Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
about
KASL clinical practice guidelines: management of chronic hepatitis BEfficacy and safety of tenofovir in chronic hepatitis B: Australian real world experienceAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Current hepatitis B treatment guidelines and future research directions.HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis BHepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective studyHepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Duck Hepatitis B Virus cccDNA Amplification Efficiency in Natural Infection Is Regulated by Virus Secretion Efficiency.Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection.A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study.Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.Virus and Host Testing to Manage Chronic Hepatitis B.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovirOn-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis BEvolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions.Recent advances in the treatment of chronic hepatitis B.Hepatitis B virus serology to predict antiviral response in chronic hepatitis B.The role of HBsAg quantification for monitoring natural history and treatment outcome.HBsAg quantification: useful for monitoring natural history and treatment outcome.HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesHBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?Virological and serological tools to optimize the management of patients with chronic hepatitis B.Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.Dual-Labeled Time-Resolved Immunofluorometric Assay for the Simultaneous Quantitative Detection of Hepatitis B Virus Antigens in Human Serum.Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
P2860
Q26752475-AC3F5034-DA92-41DA-9CAA-F168C1611FDAQ28468387-5680BF4B-D870-466C-9895-7E9FD360C3BFQ30391932-DD0B91AA-3E1F-477B-92BF-B792377AAEAFQ30487002-1610A221-AC61-4650-ACAE-142FE9BE7FD7Q30741676-3E14454E-186A-4138-8AFF-67641534096DQ30860824-4044F7D4-74DC-49D6-A369-9A0E8ED2D48DQ33721394-9A83B8CA-1220-4885-927A-7A65A94C90BAQ33958876-C389B903-A8C2-4377-A62A-039D1366A892Q34339613-E4B28459-1C2D-4A41-8FEB-D343AB1A2106Q34500227-090F150E-D246-46FB-9E6D-2172EAD0A0F9Q34674838-93E27DCB-D43A-4B05-A42B-0CCF7A9EF2D1Q35671645-CF571E6B-0AC1-4491-AF9D-F3B9B4800499Q35833216-4BBA8E8E-1D1E-4355-8720-22AAB72D56B5Q35880401-A7AAB6BF-98E9-4E58-A7CF-604E185AE668Q36050504-ACF87F74-18A3-475E-B297-C3965F6BE102Q36153966-8F54D944-6C1E-470A-8283-12324C440BB4Q36154006-FE675477-F50C-4CA0-8BCF-837B547AB84FQ36242833-796D3B41-D055-4A56-857F-B3326B72410EQ36351904-767036BC-B5C9-49C4-80B6-F8CB991D874BQ36958940-458966CE-D7B2-4B5A-8F8C-55E537CFE203Q36973383-BB36EA43-6EE0-4175-913B-003409B70896Q37334120-F3201040-340C-4E24-A6C3-EE057CD9986CQ37482902-08B70EB5-8D6E-4E71-AE4F-A8C4539570CAQ37540212-D34558F4-FC3A-405B-9055-C70ED919E40BQ37708054-C9199368-92F6-4E6B-AFA1-6FAD6A602032Q37891094-1167169E-2F8B-4DC9-B553-E3BDE2B459F3Q37966704-24FDAAE7-52A9-4D86-8939-DDC33DB2BB83Q38071397-580CF65C-2CFD-44C8-AFE4-AEDCCD609A39Q38174257-3FA189AA-69FC-4FB4-968C-96F2022B8AF4Q38174258-2B4BA7F0-3D66-4C7C-88AC-89614ED5064EQ38177851-4CA34BBF-54B7-484F-8448-88A7DEAAE5FCQ38223361-7435533D-BCEB-4D7D-8DC0-C4C74BFAFAEEQ38224440-661CA875-CC5D-43B9-8AC9-E1DFF0EB9828Q38295840-3D423C81-0677-43B4-82E9-F62C30FB38DDQ38295850-157E51B1-76F4-48AF-A67B-14C88C397A7FQ38685589-3B05F7A0-4533-4528-8A5A-289963E63BDBQ39136809-11CE9479-692C-4EF9-A0E7-7B45C1C7F87EQ39178448-2E478C98-7E3A-4D11-AAD2-C7822DA4945DQ40073140-428B29CB-2589-4A4F-86AA-859F0FE387EEQ40272794-2C1C93F4-2DF5-4894-8032-50E0BEFD0494
P2860
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Quantitative hepatitis B surfa ...... eatment response to entecavir.
@en
Quantitative hepatitis B surfa ...... eatment response to entecavir.
@nl
type
label
Quantitative hepatitis B surfa ...... eatment response to entecavir.
@en
Quantitative hepatitis B surfa ...... eatment response to entecavir.
@nl
prefLabel
Quantitative hepatitis B surfa ...... eatment response to entecavir.
@en
Quantitative hepatitis B surfa ...... eatment response to entecavir.
@nl
P2093
P2860
P356
P1433
P1476
Quantitative hepatitis B surfa ...... reatment response to entecavir
@en
P2093
Chae Yoon Chon
Do Young Kim
Hye Young Chang
Hyon Suk Kim
Jun Yong Park
Jung Min Lee
Kyu Sung Rim
Seong Gyu Hwang
P2860
P304
P356
10.1002/HEP.24221
P407
P577
2011-05-01T00:00:00Z